PD Dr. Lothar Häberle

Department of Obstetrics and Gynaecology

Trop2-expression in primary vulvar squamous cell carcinoma (2025) Stübs F, Knöll A, Hartmann A, Matek C, John N, Häberle L, Beckmann M, et al. Journal article Improving quality of care for cancer patients through oncological second opinions in a Comprehensive Cancer Center: adherence to second-opinion therapy recommendations (2025) Schulmeyer C, Fasching P, Beckmann M, Häberle L, Golcher H, Goebell P, Pöschke P, Emons J Journal article Characteristics and prognosis of patients with primary metastatic disease vs. recurrent HER2-negative, hormone receptor-positive advanced breast cancer (2025) Walter CB, Hartkopf AD, Hein A, Fasching P, Kolberg HC, Hadji P, Tesch H, et al. Journal article PD-L1-Expression in in primary and recurrent vulvar squamous cell cancer (2025) Stübs F, Knöll A, Hartmann A, Leikauf LS, Matek C, John N, Häberle L, et al. Journal article Evaluating the potential of ChatGPT for patient identification in clinical breast cancer trials (2025) Krückel A, Fasching P, Schleicher O, Gocke J, Brückner L, Seitz K, Häberle L, et al. Journal article Invasive disease-free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive, HER2-negative early breast cancer treated with upfront letrozole: Experiences from the phase IV PreFace trial (2025) Beierlein M, Häberle L, Nabieva N, Maass N, Aktas B, Kümmel S, Thomssen C, et al. Journal article Correction to: Comparative assessment of breast volume using a smartphone device versus MRI (Breast Cancer, (2025), 32, 1, (166-176), 10.1007/s12282-024-01647-6) (2025) Behrens A, Hübner H, Häberle L, Stamminger M, Zint D, Heindl F, Emons J, et al. Journal article, Erratum Malignant upgrade in lesions of uncertain malignant potential in the breast (B3 lesions) – is open excision always necessary? (2025) Heindl F, Schiel J, Hack C, Amann N, Jud S, Preuss CI, Häberle L, et al. Journal article Prediction of pathological complete response after neoadjuvant chemotherapy for HER2-negative breast cancer patients with routine immunohistochemical markers. (2025) Häberle L, Erber R, Gaß P, Hein A, Niklos M, Volz B, Hack C, et al. Journal article The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtype (2024) Ziegler P, Hartkopf AD, Wallwiener M, Häberle L, Kolberg HC, Hadji P, Tesch H, et al. Journal article